Clinical trials: Cognitive Disorder
Huntington Disease
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F.
- Trial name
- NCT03842969
- Testing
- RO7234292 (RG6042)
- Where
- 38 sites in United States, Austria and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Neurocognitive Dysfunction
A Test of Neural Inertia in Humans With Xenon
The dual objectives of this study are to determine if the phenomenon of neural inertia is present in humans and to determine whether the order of neurocognitive function is invariant among anesthetic agents.
- Trial name
- NCT02768727
- Testing
- Xenon
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Parkinson's Disease, Mild Cognitive Impairment
Mild Cognitive Impairment in Parkinson's Disease
Mild cognitive impairment, including difficulty with solving problems, planning, attention, or recalling information, can be a significant problem for individuals with Parkinson's disease.
- Trial name
- NCT01519271
- Testing
- Exelon Patch (rivastigmine transdermal system)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Huntington's Disease
Coenzyme Q10 in Huntington's Disease (HD)
The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its…
- Trial name
- 2CARE (NCT00608881)
- Testing
- coenzyme Q10
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 609 people
- Sponsor
- Massachusetts General Hospital
Nicotine Dependence, Nicotine Withdrawal
Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
The objective of this proposal is to elucidate effects of bupropion SR + varenicline on smoking-cessation related processes in early abstinence using a human laboratory model.
- Trial name
- ChanBan (NCT00749658)
- Testing
- Bupropion, Varenicline
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Cognitive Decline
Evaluation of Cognitive State in Seniors Using Neurosteer EEG System
This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through EEG recordings while listening to an…
- Trial name
- NCT05528445
- Testing
- Neurosteer EEG recorder
- Where
- Israel
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Neurosteer Ltd.
Schizophrenia
C-Cog in Early Course Schizophrenia Study
The purpose of this study is to examine the role of clinical stability in functional recovery. in first episode schizophrenia.
- Trial name
- NCT05662306
- Testing
- Aripiprazole Lauroxil, Computerized cognitive and functional skills training
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Transcranial Direct Current Stimulation, Schizophrenia
Maximizing the Impact of Neuroplasticity Using Transcranial Electrical Stimulation Study 2
Non-invasive neuromodulation, such as transcranial direct current stimulation ( tDCS) , is emerging as an important therapeutic tool with documented effects on brain circuitry, yet little is understood about h ow it changes…
- Conditions
- Transcranial Direct Current Stimulation, Schizophrenia, Schizoaffective Disorder
- Trial name
- MINUTES (NCT03896438)
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Minnesota
Type 2 Diabetes Mellitus, Cognitive Impairment
Intensive Aerobic and Resistance Exercise Program (IAREP)
A 12-week Intensive Aerobic and Resistance Exercise Program (IAREP) intervention was implemented on high-risk and low-risk subjects with cognitive impairment in type 2 Diabetes Mellitus.
- Conditions
- Type 2 Diabetes Mellitus, Cognitive Impairment, Non-insulin-dependent Diabetes Mellitus, Cognitive Dysfunction
- Trial name
- NCT06401733
- Testing
- Intensive Aerobic and Resistance Exercise Program (IAREP)
- Where
- Singapore
- Volunteers
- 58 people
- Sponsor
- National University of Singapore
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Binge-Eating Disorder, Obesity
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity.
- Trial name
- NCT03946111
- Testing
- Naltrexone and Bupropion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Delirium, Alzheimer Disease
Improving the Recovery and Outcome Every Day After the ICU
Primary Specific Aim: Determine the effect of the combined physical exercise and cognitive training on the cognitive function of ICU survivors aged 50 and older.
- Trial name
- IMPROVE (NCT03095417)
- Testing
- Physical Exercise Intervention, Cognitive Training Intervention, Stretching Control
- Where
- 6 sites in United States
- Volunteers
- 249 people
- Sponsor
- Indiana University
Parkinson Disease
Cognitive Training in Parkinson's Disease
The purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with Parkinson's Disease (PD) during activities of daily living using cognitive evaluations and…
- Trial name
- NCT05495997
- Testing
- Mental Imagery Training, Psychoeducation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Drug Toxicity
MW151-101: First-in-human Study of MW151
MW01-2-151SRM (=MW151), a small molecule, is being developed for the treatment of cognitive disorders. The development program is based on nonclinical evidence that MW151 improves neurocognitive outcomes in animal models of…
- Trial name
- NCT04120233
- Testing
- MW151, 10mg, MW151, 20mg, MW151, 40mg
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Linda Van Eldik
Mild Cognitive Impairment, Caregiver Burnout
Improving Physical Activity With Cognitive Impairment
Individuals with mild cognitive impairment are often physically inactive and at risk for progressing to dementia. Physical inactivity is considered a modifiable risk factor for dementia.
- Trial name
- NCT05370118
- Testing
- Telerehabilitation physical activity behavioral (TPAB) intervention
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Creighton University
Insomnia
Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention
Chronic insomnia is one of the most common health problems among Veterans and significantly impacts their health, function, and quality of life.
- Trial name
- SEDATIVE (NCT05027438)
- Testing
- Cognitive Behavioral Therapy for Insomnia, Deprescribing
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- VA Office of Research and Development
Adolescents, Mood Disorders
Mobile-enhanced Group CBT for Adolescents at Risk Severe Mood Disorders
Although cognitive-behavioral therapy (CBT) has shown efficacy in reducing symptoms and rates of mood relapse in adolescents at high risk for severe mood disorders (SMD; i.e., bipolar I/II disorder and recurrent or unremitting…
- Trial name
- NCT04887155
- Testing
- Cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- University of California, Los Angeles
Atrial Fibrillation
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin.
- Trial name
- ARISTA (NCT03839355)
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Heart Failure, Cognition Disorders
Cognitive Problems in Veterans With Heart Failure
We assessed the prevalence of cognitive/memory problems in veteran patients with heart failure, and evaluated its relationship to medication compliance.
- Trial name
- NCT01049308
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- US Department of Veterans Affairs
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.